Kilitch Drugs(I) Share Price
Start SIP in Kilitch Drugs(I)
Start SIPKilitch Drugs(I) Performance
Day Range
- Low 363
- High 387
52 Week Range
- Low 224
- High 470
- Open Price372
- Previous Close370
- Volume18384
Kilitch Drugs(I) Investment Rating
-
Master Rating:
-
Kilitch Drugs India has an operating revenue of Rs. 151.27 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 13% is healthy, ROE of 8% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 200DMA and around 8% above its 50DMA. It needs to stay above the 200DMA levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 21% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 61 which is a FAIR score but needs to improve its earnings, a RS Rating of 49 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 54 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 33 | 39 | 30 | 32 | 31 | 43 |
Operating Expenses Qtr Cr | 30 | 34 | 26 | 26 | 26 | 37 |
Operating Profit Qtr Cr | 3 | 5 | 4 | 6 | 5 | 7 |
Depreciation Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Qtr Cr | 0 | 0 | 1 | 0 | 0 | 0 |
Tax Qtr Cr | 2 | 2 | 1 | 2 | 1 | 2 |
Net Profit Qtr Cr | 4 | 4 | 5 | 4 | 4 | 5 |
Kilitch Drugs(I) Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 12
- Bearish Moving Average
- ___
- 4
- 20 Day
- ₹360.67
- 50 Day
- ₹351.21
- 100 Day
- ₹348.91
- 200 Day
- ₹336.64
- 20 Day
- ₹353.46
- 50 Day
- ₹348.98
- 100 Day
- ₹343.82
- 200 Day
- ₹361.97
Kilitch Drugs(I) Resistance and Support
Resistance | |
---|---|
First Resistance | 386.07 |
Second Resistance | 401.73 |
Third Resistance | 414.67 |
RSI | 57.65 |
MFI | 73.09 |
MACD Single Line | 7.40 |
MACD | 11.23 |
Support | |
---|---|
First Support | 357.47 |
Second Support | 344.53 |
Third Supoort | 328.87 |
Kilitch Drugs(I) Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 34,206 | 1,102,459 | 32.23 |
Week | 42,583 | 1,371,160 | 32.2 |
1 Month | 31,661 | 1,461,769 | 46.17 |
6 Month | 20,131 | 1,075,389 | 53.42 |
Kilitch Drugs(I) Result Highlights
Kilitch Drugs(I) Synopsis
NSE-Medical-Diversified
Kilitch Drugs(I) is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 117.78 Cr. and Equity Capital is Rs. 15.58 Cr. for the Year ended 31/03/2023. Kilitch Drugs(I) Ltd. is a Public Limited Listed company incorporated on 12/05/1992 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1992PLC066718 and registration number is 066718.Market Cap | 596 |
Sales | 134 |
Shares in Float | 0.50 |
No of funds | 1 |
Yield | 0.51 |
Book Value | 2.67 |
U/D Vol ratio | 2.2 |
LTDebt / Equity | |
Alpha | 0.14 |
Beta | 0.76 |
Kilitch Drugs(I) Shareholding Pattern
Owner Name | Jun-24 | Mar-24 | Dec-23 | Sep-23 |
---|---|---|---|---|
Promoters | 69.23% | 69.23% | 69.23% | 69.23% |
Foreign Portfolio Investors | ||||
Financial Institutions/ Banks | ||||
Individual Investors | 25.21% | 25.38% | 26.13% | 26.13% |
Others | 5.56% | 5.39% | 4.64% | 4.64% |
Kilitch Drugs(I) Management
Name | Designation |
---|---|
Mr. Mukund P Mehta | Managing Director |
Mr. Bhavin Mukund Mehta | Whole Time Director |
Mrs. Mira B Mehta | Whole Time Director |
Mr. Hemang J Engineer | Independent Director |
Mr. Venkita Subramanian Rajan | Independent Director |
Prof. Vasudev Krishna Murti | Independent Director |
Kilitch Drugs(I) Forecast
Price Estimates
Kilitch Drugs(I) Corporate Action
Date | Purpose | Remarks |
---|---|---|
2024-08-08 | Quarterly Results | |
2024-05-27 | Quarterly Results | |
2024-02-08 | Quarterly Results | |
2023-11-09 | Quarterly Results | |
2023-08-11 | Quarterly Results |
Kilitch Drugs(I) FAQs
What is Share Price of Kilitch Drugs(I) ?
Kilitch Drugs(I) share price is ₹369 As on 19 September, 2024 | 19:27
What is the Market Cap of Kilitch Drugs(I) ?
The Market Cap of Kilitch Drugs(I) is ₹593.9 Cr As on 19 September, 2024 | 19:27
What is the P/E ratio of Kilitch Drugs(I) ?
The P/E ratio of Kilitch Drugs(I) is 47.2 As on 19 September, 2024 | 19:27
What is the PB ratio of Kilitch Drugs(I) ?
The PB ratio of Kilitch Drugs(I) is 3.4 As on 19 September, 2024 | 19:27